VNRX - VOLITIONRX LTD
vs
Region: US
Website: volition.com
Employees: 80
IPO year: 2011
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing
VolitionRx Limited engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; NuQ Nets, monitoring the immune system, and NuQ Vet cancer screening test for veterinary applications. The company operates Nucleosomics a technology platform.
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
VolitionRX Ltd (VNRX) reports a 59% revenue increase, driven by the Nu.Q Vet Cancer Test, while reducing operating expenses and advancing key studies and licensing deals.
Read moreVolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024. Volition management will host a conference call today, March 31 at 4:30 p.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
Read moreVolition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q® H3K27Me3 biomarker, when combined with circulating tumor DNA, may improve the prognostic value for overall survival and could help inform treatment decisions in Non Small Cell Lung Cancer (NSCLC); and how Volition's Nu.
Read more